AusPAR Attachment 1: Product Information for Silodosin

The responder rate (i.e. improvement in the IPSS total score by at least 25 %) was significantly higher in the silodosin (68 %) and tamsulosin group (65 %), as compared to placebo (53 %). In the long-term open-label extension phase of these controlled studies, in which patients received silodosin for up to 1 year, the symptom improvement ... ................
................